Tumor lysis syndrome after transcatheter arterial infusion of cisplatin and embolization therapy for liver metastases of melanoma.
BACKGROUND
Tumor lysis syndrome (TLS) is rare in the treatment of solid tumors, but it may occur in myelolymphoproliferative diseases.


METHODS
A 58-year-old man with bulky metastatic melanoma of the liver was treated with transcatheter arterial infusion of cisplatin and embolization therapy. The patient developed classic signs of TLS within 24 h of chemotherapy, including acute renal failure.


RESULTS
The patient was treated with aggressive hydration, allopurinol, and repeated hemodialysis. He gradually improved and his biochemical markers returned to normal.


CONCLUSIONS
TLS is an uncommon, but potentially life-threatening, complication in melanoma and other solid tumors. It is important for oncologists to recognize this complication and prevent its development if bulky metastatic disease and several pre-existing risk factors, such as multiple and bulky liver metastases, elevated lactate dehydrogenase, and hyperuricemia, are present.
Nakamura
Yoshiyuki
Y
Department of Dermatology, University of Tsukuba, Japan.
Nakamura
Yasuhiro
Y
Hori
Enmi
E
Furuta
Junichi
J
Ishii
Yoshiyuki
Y
Takahashi
Takenori
T
Kawachi
Yasuhiro
Y
Otsuka
Fujio
F
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects*; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D012878:Skin Neoplasms / Q000473:pathology; D015275:Tumor Lysis Syndrome / Q000209:etiology* / Q000628:therapy
D000970:Antineoplastic Agents; D002945:Cisplatin